From single-dose vaccine delivery systems to nanovaccines (Q59342615)

1

0 references

C. Prego

2

0 references

N. Csaba

3

0 references

M.J. Alonso

Journal of Drug Delivery Science and Technology

4

0 references

publication date

2010

0 references

published in

0 references

volume

20

0 references

issue

4

0 references

page(s)

267-276

0 references

cites work

The safety of vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS1773-2247%2810%2950044-3

7 January 2021

Vaccines: past, present and future

1 reference

https://api.crossref.org/works/10.1016%2FS1773-2247%2810%2950044-3

7 January 2021

DNA vaccines: a review

1 reference

https://api.crossref.org/works/10.1016%2FS1773-2247%2810%2950044-3

7 January 2021

The use of genomics in microbial vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FS1773-2247%2810%2950044-3

7 January 2021

Need for new vaccine formulations and potential of particulate antigen and DNA delivery systems

1 reference

https://api.crossref.org/works/10.1016%2FS1773-2247%2810%2950044-3

7 January 2021

Global health. The new world of global health

1 reference

https://api.crossref.org/works/10.1016%2FS1773-2247%2810%2950044-3

7 January 2021

Freezing temperatures in the vaccine cold chain: a systematic literature review

1 reference

https://api.crossref.org/works/10.1016%2FS1773-2247%2810%2950044-3

7 January 2021

Mechanism of freeze-thaw instability of aluminum hydroxycarbonate and magnesium hydroxide gels

1 reference

https://api.crossref.org/works/10.1016%2FS1773-2247%2810%2950044-3

7 January 2021

Is the cold chain for vaccines maintained in general practice?

1 reference

https://api.crossref.org/works/10.1016%2FS1773-2247%2810%2950044-3

7 January 2021

Stabilization of measles virus for vaccine formulation

1 reference

https://api.crossref.org/works/10.1016%2FS1773-2247%2810%2950044-3

7 January 2021

Characterization of a thermostable hepatitis B vaccine formulation

1 reference

https://api.crossref.org/works/10.1016%2FS1773-2247%2810%2950044-3

7 January 2021

Drying-induced variations in physico-chemical properties of amorphous pharmaceuticals and their impact on Stability II: stability of a vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1773-2247%2810%2950044-3

7 January 2021

Rational design of a stable, freeze-dried virus-like particle-based vaccine formulation

1 reference

https://api.crossref.org/works/10.1016%2FS1773-2247%2810%2950044-3

7 January 2021

Future approaches to vaccine development: single-dose vaccines using controlled-release delivery systems

1 reference

https://api.crossref.org/works/10.1016%2FS1773-2247%2810%2950044-3

7 January 2021

Combination vaccines consisting of acellular pertussis vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FS1773-2247%2810%2950044-3

7 January 2021

Technologies that make administration of vaccines safer

1 reference

https://api.crossref.org/works/10.1016%2FS1773-2247%2810%2950044-3

7 January 2021

Ensuring vaccine safety in immunization programmes--a WHO perspective

1 reference

https://api.crossref.org/works/10.1016%2FS1773-2247%2810%2950044-3

7 January 2021

The global impact of vaccines containing aluminium adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FS1773-2247%2810%2950044-3

7 January 2021

Aluminium adjuvants--in retrospect and prospect

1 reference

https://api.crossref.org/works/10.1016%2FS1773-2247%2810%2950044-3

7 January 2021

(How) do aluminium adjuvants work?

1 reference

https://api.crossref.org/works/10.1016%2FS1773-2247%2810%2950044-3

7 January 2021

Safety of MF59 adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FS1773-2247%2810%2950044-3

7 January 2021

GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives

1 reference

https://api.crossref.org/works/10.1016%2FS1773-2247%2810%2950044-3

7 January 2021

Immunogenicity and tolerability of an AS03(A)-adjuvanted prepandemic influenza vaccine: a phase III study in a large population of Asian adults.

1 reference

https://api.crossref.org/works/10.1016%2FS1773-2247%2810%2950044-3

7 January 2021

Vaccine adjuvants: current challenges and future approaches.

1 reference

https://api.crossref.org/works/10.1016%2FS1773-2247%2810%2950044-3

7 January 2021

Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens

1 reference

https://api.crossref.org/works/10.1016%2FS1773-2247%2810%2950044-3

7 January 2021

Immunological concepts of vaccine adjuvant activity

1 reference

https://api.crossref.org/works/10.1016%2FS1773-2247%2810%2950044-3

7 January 2021

Distinct pathways of antigen uptake and intracellular routing in CD4 and CD8 T cell activation.

1 reference

https://api.crossref.org/works/10.1016%2FS1773-2247%2810%2950044-3

7 January 2021

Dendritic cells and the control of immunity

1 reference

https://api.crossref.org/works/10.1016%2FS1773-2247%2810%2950044-3

7 January 2021

Immunity in response to particulate antigen-delivery systems

1 reference

https://api.crossref.org/works/10.1016%2FS1773-2247%2810%2950044-3

7 January 2021

Surface proteins involved in T cell costimulation

1 reference

https://api.crossref.org/works/10.1016%2FS1773-2247%2810%2950044-3

7 January 2021

The relevance of cytokines for development of protective immunity and rational design of vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS1773-2247%2810%2950044-3

7 January 2021

Enhanced immune response to DNA-based HPV16L1 vaccination by costimulatory molecule B7-2

1 reference

https://api.crossref.org/works/10.1016%2FS1773-2247%2810%2950044-3

7 January 2021

Toll-like receptors and innate immunity

1 reference

https://api.crossref.org/works/10.1016%2FS1773-2247%2810%2950044-3

7 January 2021

Triggering TLR signaling in vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS1773-2247%2810%2950044-3

7 January 2021

Modulation of adaptive immunity with Toll-like receptors

1 reference

https://api.crossref.org/works/10.1016%2FS1773-2247%2810%2950044-3

7 January 2021

AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity

1 reference

https://api.crossref.org/works/10.1016%2FS1773-2247%2810%2950044-3

7 January 2021

Translating innate immunity into immunological memory: implications for vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FS1773-2247%2810%2950044-3

7 January 2021

Pathogen recognition and development of particulate vaccines: does size matter?

1 reference

https://api.crossref.org/works/10.1016%2FS1773-2247%2810%2950044-3

7 January 2021

Improved immunogenicity of a core-coated tetanus toxoid delivery system

1 reference

https://api.crossref.org/works/10.1016%2FS1773-2247%2810%2950044-3

7 January 2021

Delivery by Cationic Gelatin Nanoparticles Strongly Increases the Immunostimulatory Effects of CpG Oligonucleotides

1 reference

https://api.crossref.org/works/10.1016%2FS1773-2247%2810%2950044-3

7 January 2021

Polymerized micelles and their use as adjuvants in immunology

1 reference

https://api.crossref.org/works/10.1016%2FS1773-2247%2810%2950044-3

7 January 2021

A single-step immunization by sustained antigen release

1 reference

https://api.crossref.org/works/10.1016%2FS1773-2247%2810%2950044-3

7 January 2021

Nanoparticles for nasal vaccination.

1 reference

https://api.crossref.org/works/10.1016%2FS1773-2247%2810%2950044-3

7 January 2021

Nanoparticles as protein and gene carriers to mucosal surfaces.

1 reference

https://api.crossref.org/works/10.1016%2FS1773-2247%2810%2950044-3

7 January 2021

Nanoparticles as carriers for nasal vaccine delivery.

1 reference

https://api.crossref.org/works/10.1016%2FS1773-2247%2810%2950044-3

7 January 2021

Nanoparticles and microparticles as vaccine-delivery systems

1 reference

https://api.crossref.org/works/10.1016%2FS1773-2247%2810%2950044-3

7 January 2021

Enhanced immunogenicity of microencapsulated tetanus toxoid with stabilizing agents

1 reference

https://api.crossref.org/works/10.1016%2FS1773-2247%2810%2950044-3

7 January 2021

Biodegradable microspheres containing influenza A vaccine: immune response in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1773-2247%2810%2950044-3

7 January 2021

A novel system based on a poloxamer/PLGA blend as a tetanus toxoid delivery vehicle

1 reference

https://api.crossref.org/works/10.1016%2FS1773-2247%2810%2950044-3

7 January 2021

Development of a single-dose stabilized poly(D,L-lactic-co-glycolic acid) microspheres-based vaccine against hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1773-2247%2810%2950044-3

7 January 2021

Pharmaceutical and immunological evaluation of a single-dose hepatitis B vaccine using PLGA microspheres.

1 reference

https://api.crossref.org/works/10.1016%2FS1773-2247%2810%2950044-3

7 January 2021

The use of soluble polymers and polymer microparticles to provide improved vaccine responses after parenteral and mucosal delivery

1 reference

https://api.crossref.org/works/10.1016%2FS1773-2247%2810%2950044-3

7 January 2021

Biodegradable microspheres as controlled-release tetanus toxoid delivery systems.

1 reference

https://api.crossref.org/works/10.1016%2FS1773-2247%2810%2950044-3

7 January 2021

Pulsed controlled-released system for potential use in vaccine delivery

1 reference

https://api.crossref.org/works/10.1016%2FS1773-2247%2810%2950044-3

7 January 2021

Molecular aspects of microparticle phagocytosis by dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS1773-2247%2810%2950044-3

7 January 2021

Phenotype and functional analysis of human monocyte-derived dendritic cells loaded with biodegradable poly(lactide-co-glycolide) microspheres for immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1773-2247%2810%2950044-3

7 January 2021

Determinants of release rate of tetanus vaccine from polyester microspheres.

1 reference

https://api.crossref.org/works/10.1016%2FS1773-2247%2810%2950044-3

7 January 2021

Tetanus toxoid microspheres consisting of biodegradable poly(lactide-co-glycolide)- and ABA-triblock-copolymers: immune response in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1773-2247%2810%2950044-3

7 January 2021

Improving stability and release kinetics of microencapsulated tetanus toxoid by co-encapsulation of additives

1 reference

https://api.crossref.org/works/10.1016%2FS1773-2247%2810%2950044-3

7 January 2021

New strategies for the microencapsulation of tetanus vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FS1773-2247%2810%2950044-3

7 January 2021

Stabilization of tetanus toxoid in poly(DL-lactic-co-glycolic acid) microspheres for the controlled release of antigen

1 reference

https://api.crossref.org/works/10.1016%2FS1773-2247%2810%2950044-3

7 January 2021

Stabilization of tetanus and diphtheria toxoids against moisture-induced aggregation

1 reference

https://api.crossref.org/works/10.1016%2FS1773-2247%2810%2950044-3

7 January 2021

Formulation strategies for the stabilization of tetanus toxoid in poly(lactide-co-glycolide) microspheres.

1 reference

https://api.crossref.org/works/10.1016%2FS1773-2247%2810%2950044-3

7 January 2021

Chronic local tissue reactions, long-term immunogenicity and immunologic priming of mice and guinea pigs to tetanus toxoid encapsulated in biodegradable polymer microspheres composed of poly lactide-co-glycolide polymers.

1 reference

https://api.crossref.org/works/10.1016%2FS1773-2247%2810%2950044-3

7 January 2021

Improved immune response from biodegradable polymer particles entrapping tetanus toxoid by use of different immunization protocol and adjuvants.

1 reference

https://api.crossref.org/works/10.1016%2FS1773-2247%2810%2950044-3

7 January 2021

Formulation and characterization of immunoreactive tetanus toxoid biodegradable polymer particles

1 reference

https://api.crossref.org/works/10.1016%2FS1773-2247%2810%2950044-3

7 January 2021

Chitosan-based nanoparticles for improving immunization against hepatitis B infection.

1 reference

https://api.crossref.org/works/10.1016%2FS1773-2247%2810%2950044-3

7 January 2021

Needle-free vaccine delivery

1 reference

https://api.crossref.org/works/10.1016%2FS1773-2247%2810%2950044-3

7 January 2021

Mucosal vaccines: the promise and the challenge

1 reference

https://api.crossref.org/works/10.1016%2FS1773-2247%2810%2950044-3

7 January 2021

Mucosal immunity and vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS1773-2247%2810%2950044-3

7 January 2021

Immune response to nasal delivery of antigenically intact tetanus toxoid associated with poly(L-lactic acid) microspheres in rats, rabbits and guinea-pigs

1 reference

https://api.crossref.org/works/10.1016%2FS1773-2247%2810%2950044-3

7 January 2021

Microsphere translocation and immunopotentiation in systemic tissues following intranasal administration

1 reference

https://api.crossref.org/works/10.1016%2FS1773-2247%2810%2950044-3

7 January 2021

Transport of PLA-PEG particles across the nasal mucosa: effect of particle size and PEG coating density.

1 reference

https://api.crossref.org/works/10.1016%2FS1773-2247%2810%2950044-3

7 January 2021

PLA-PEG particles as nasal protein carriers: the influence of the particle size.

1 reference

https://api.crossref.org/works/10.1016%2FS1773-2247%2810%2950044-3

7 January 2021

Design of biodegradable particles for protein delivery

1 reference

https://api.crossref.org/works/10.1016%2FS1773-2247%2810%2950044-3

7 January 2021

Nanoparticle uptake by the rat gastrointestinal mucosa: quantitation and particle size dependency

1 reference

https://api.crossref.org/works/10.1016%2FS1773-2247%2810%2950044-3

7 January 2021

Oral vaccination in man using antigens in particles: current status

1 reference

https://api.crossref.org/works/10.1016%2FS1773-2247%2810%2950044-3

7 January 2021

Tetanus toxoid loaded nanoparticles from sulfobutylated poly(vinyl alcohol)-graft-poly(lactide-co-glycolide): evaluation of antibody response after oral and nasal application in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1773-2247%2810%2950044-3

7 January 2021

M-cell targeted biodegradable PLGA nanoparticles for oral immunization against hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1773-2247%2810%2950044-3

7 January 2021

Evaluation of the immune response following a short oral vaccination schedule with hepatitis B antigen encapsulated into alginate-coated chitosan nanoparticles

1 reference

https://api.crossref.org/works/10.1016%2FS1773-2247%2810%2950044-3

7 January 2021

Uptake studies in rat Peyer's patches, cytotoxicity and release studies of alginate coated chitosan nanoparticles for mucosal vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS1773-2247%2810%2950044-3

7 January 2021

https://api.crossref.org/works/10.1016%2FS1773-2247%2810%2950044-3

1 reference

7 January 2021

Protein-loaded PLGA–PEO blend nanoparticles: encapsulation, release and degradation characteristics

1 reference

https://api.crossref.org/works/10.1016%2FS1773-2247%2810%2950044-3

7 January 2021

PLGA:poloxamer and PLGA:poloxamine blend nanostructures as carriers for nasal gene delivery

1 reference

https://api.crossref.org/works/10.1016%2FS1773-2247%2810%2950044-3

7 January 2021

PEG-PLA nanoparticles as carriers for nasal vaccine delivery

1 reference

https://api.crossref.org/works/10.1016%2FS1773-2247%2810%2950044-3

7 January 2021

Low molecular weight chitosan nanoparticles as new carriers for nasal vaccine delivery in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1773-2247%2810%2950044-3

7 January 2021

Ionically crosslinked chitosan/tripolyphosphate nanoparticles for oligonucleotide and plasmid DNA delivery.

1 reference

https://api.crossref.org/works/10.1016%2FS1773-2247%2810%2950044-3

7 January 2021

Ionically crosslinked chitosan nanoparticles as gene delivery systems: effect of PEGylation degree on in vitro and in vivo gene transfer

1 reference

https://api.crossref.org/works/10.1016%2FS1773-2247%2810%2950044-3

7 January 2021

N-trimethyl chitosan (TMC) nanoparticles loaded with influenza subunit antigen for intranasal vaccination: biological properties and immunogenicity in a mouse model

1 reference

https://api.crossref.org/works/10.1016%2FS1773-2247%2810%2950044-3

7 January 2021

Nanotechnology in vaccine delivery

1 reference

https://api.crossref.org/works/10.1016%2FS1773-2247%2810%2950044-3

7 January 2021